Egetis Therapeutics AB · OMXSTO:EGTX

Egetis Therapeutics AB — Investor Presentation (March 2026)

101 slides from Egetis Therapeutics AB's investor presentation, March 2026

  1. Slide 1: We Care for the Rare – Corporate presentation March 2026

    WE CARE FOR THE RARE Corporate presentation March 2026 Emcitate® (tiratricol) launched in Germany in May 2025 Rolling U.S. NDA completed in January 2026 For investors and analysts only ©2026 Egetis Therapeutics. All rights reserved. 1

  2. Slide 2: Disclaimer

    Disclaimer Tiratricol is an investigational drug and has not been approved by the U.S. Food and Drug Administration (FDA). Its safety and efficacy have not been established in the U.S. THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY

  3. Slide 3: An integrated orphan drug company

    WE CARE FOR THE RARE 1. An integrated orphan drug company, focusing on late-stage development and commercialization

  4. Slide 4: Egetis: building an orphan drug commercial stage company

    Egetis: building an orphan drug commercial stage company Focus on Emcitate® (tiratricol) for the treatment of MCT8 deficiency 1 Supplied to over 230 patients in over 25 countries including US, EU Strong regulatory status The first and only approved drug for the treatment of MCT8 deficiency BTD Break

  5. Slide 5: Strong Execution in 2025 Positions Egetis for Emcitate U.S. Launch in 2026

    Strong Execution in 2025 Positions Egetis for Emcitate U.S. Launch in 2026 ✓ Japan – Development plan alignment with Expected launch of EC approves Emcitate Emcitate in the U.S. Positive Phase 3 PMDA as first and only FDA Breakthrough ReTRIACt withdrawal ✓ Completion of NDA treatment for MCT8 Therap

  6. Slide 6: MCT8 deficiency results in dysfunctional thyroid hormone trafficking

    MCT8 deficiency results in dysfunctional thyroid hormone trafficking Median life expectancy of 35 years with 30% of patients dying in childhood MCT8 deficiency key features Estimated incidence: 1 per 70k male births Median onset of symptoms: 4 months Median age of diagnosis: 10 months Median life ex

  7. Slide 7: Emcitate (tiratricol) mechanism of action

    Emcitate® (tiratricol) mechanism of action with clear scientific and mechanistic rationale Cellular membrane • Tiratricol is a small molecule, thyroid hormone agonist Tiratricol in action Tiratricol • Unlike T3, tiratricol can cross cellular membranes without a TR functional MCT8 transporter T3 With

  8. Slide 8: Tiratricol treatment associated with survival benefits

    Tiratricol treatment in patients with MCT8 deficiency has been shown to be associated with survival benefits In the Triac Trial I, tiratricol reached target level serum T3 & improvements Tiratricol has been shown to be in clinically relevant outcome measures associated with a 3x lower risk of mortal

  9. Slide 9: Emcitate approved in EU and launched in Germany; NDA completed

    Emcitate® (tiratricol) Approved in EU and Launched in Germany; Rolling NDA Initiated Dec 2025; NDA Completed Jan 2026 Robust dataset in an ultra rare genetic disease; all FDA-required studies completed EMC cohort U.S. Expanded Triac Trial I Triac Trial II Survival study ReTRIACt study Access Program

  10. Slide 10: Tiratricol's Effect on T3 Lowering May Explain Mortality Benefit

    Tiratricol’s Effect on T3 Lowering May Explain Mortality Benefit Emcitate Source for evidence of (tiratricol) efficacy T3 Triac Trial I, Triac Trial II, ReTRIACt, EMC Cohort Study Triac Trial I, Immune Body weight HR BP Arrhythmia EMC Cohort system Study RPP Triac Trial I, ReTRIACt Infection Sudden

  11. Slide 11: Emcitate launch by Egetis and partners

    Emcitate® (tiratricol) launch by Egetis and partners Executing the US & European market preparations and launches through the Egetis team To optimize the launch, we will focus our own resources on US and Europe Optimizing additional Japan license deal with countries through partners Fujimoto Türkiye

  12. Slide 12: ETA Recommends Emcitate as Long-Term Therapy for MCT8 Deficiency

    European Thyroid Association (ETA) Recommends Emcitate (tiratricol) as Long-Term Therapy for MCT8 Deficiency ETA recommends the use of tiratricol as long-term therapy for all patients with MCT8 deficiency, and for certain patients with RTHβ Inaugural 2024 Guidelines were commissioned by the Executiv

  13. Slide 13: A phased EU launch through in-house commercial organization

    A phased EU launch through in-house commercial organization started in Germany in May 2025 Launch execution in 2 waves, starting with EU4 Deliver the Emcitate clinical and economic value proposition in P&R processes, outlining: Wave 1 • MCT8 deficiency and its rarity Germany, France, Italy, Spain &

  14. Slide 14: Europe & International

    Europe & International Building on positive 2025 momentum to optimize access and sales opportunities further • Strong close to 2025 - Full-year sales MSEK 62.3, +40% vs. 2024 (CER) • European pricing & reimbursement (P&R) advancement ‒ Germany: Progressing well; final reimbursed price in Q2 2026 ‒ F

  15. Slide 15: United States: Egetis Priority Market

    United States: Egetis Priority Market From Regulatory Milestone to Commercial Momentum Driving Patient Identification Growth • Deep engagement in key referral centers • Strong KOL and advocacy alignment • Growing identified patient pool (>140) Expanded Access Strengthening Launch Readiness • 17 acti

  16. Slide 16: US: Annual Treatment Costs and Strength of Evidence

    US: Annual Treatment Costs and Strength of Evidence Representative analogues Product Disease Estimated avg. annual treatment cost (WAC) Impact of strength of evidence on price Oxlumo® Primary ~$623K Biologic hyperoxaluria type 1 • Morbidity-driven disease burden, supported by Hypophosphatasia surviv

  17. Slide 17: Resistance to Thyroid Hormone Type Beta (RTH-β)

    Resistance to Thyroid Hormone Type Beta (RTH-β) Potential indication expansion for Emcitate into larger non-overlapping patient population Characteristics of RTH-β Emcitate as potential treatment for RTH-β • Caused by mutations in thyroid hormone receptor beta (TRβ)1 • Emcitate efficacious in restor

  18. Slide 18: Strong financial foundation for strategic execution

    Strong financial foundation for strategic execution Solid cash position Directed share issue Oct. 2025 of SEK 183m (USD 19m) • Cash position December 31, 2025: SEK 216 million • Oversubscribed with participation from new & existing investors • Number of outstanding shares: 395,161,938 • Market Cap:

  19. Slide 19: Financial Overview – Fourth Quarter and 12-months

    Financial Overview – Fourth Quarter and 12-months • Total revenue ‒ FY-2025 of 62.4 MSEK vs. 46.1 MSEK for 2024, +40% YoY CER ‒ Q4-2025 of 17.9 MSEK vs. 10.8 MSEK for Q4-2024, +74% YoY CER • Cost of goods sold impacted by non-recurring milestone and the initiation of MSEK 2025 2024 2025 2024 intangi

  20. Slide 20: Strong Execution in 2025 Positions Egetis for Emcitate U.S. Launch in 2026

    Strong Execution in 2025 Positions Egetis for Emcitate U.S. Launch in 2026 ✓ Japan – Development plan alignment with Expected launch of EC approves Emcitate Emcitate in the U.S. Positive Phase 3 PMDA as first and only FDA Breakthrough ReTRIACt withdrawal ✓ Completion of NDA treatment for MCT8 Therap

  21. Slide 21: Pipeline Overview

    Pipeline Overview Emcitate® (tiratricol) – Launched in Germany May 2025; NDA submitted in the U.S. in January 2026 Candidate Preclinical Phase I Phase II / III MAA / NDA Comments Emcitate EU EC approval received Feb 12, 2025 Launched MCT8 deficiency Launched in Germany May 1, 2025 Tiratricol U.S. Ro

  22. Slide 22: Building a sustainable orphan drug company

    Building a sustainable orphan drug company • Successfully develop Emcitate for EU & US approvals in 2025/26 and potentially Aladote post 2026 • Commercialize Emcitate and Aladote through an inhouse organization in Europe/ North America and partnerships in RoW • Realize the full potential of our prod

  23. Slide 23: Appendix 1: Overview of MCT8 deficiency

    Appendix 1 Overview of MCT8 deficiency 23

  24. Slide 24: MCT8 deficiency results in dysfunctional thyroid hormone trafficking

    MCT8 deficiency results in dysfunctional thyroid hormone trafficking MCT8 deficiency has two co-manifestations MCT8 deficiency results in simultaneous too high and too low New Research Sheds Light on Thyroid Hormone Transport thyroid hormone levels – causing system wide issues • In 2003, MCT8 was id

  25. Slide 25: MCT8 deficiency: a detrimental condition with significant unmet medical need

    MCT8 deficiency: a detrimental condition with significant unmet medical need What is MCT8 deficiency? What does it mean? What are the challenges? How do you manage the Quick facts from natural history2 disease? • Genetic X-linked disorder ● Non-functional MCT8 protein: ● Patients appear normal at bi

  26. Slide 26: Natural history study revealed poor survival

    Natural history study revealed poor survival with a high prevalence of treatable underlying risk factors An international, retrospective, multicentre cohort study from 2014-2020 in 151 patients • 151 patients were enrolled with 73 different MCT8 (SLC16A2) mutations • Median age at diagnosis was 24.0

  27. Slide 27: Multiple sources lead to consistent MCT8 deficiency incidence estimates

    Multiple sources lead to consistent MCT8 deficiency incidence estimates Available Data Leads to Consistent Supporting our Relevant Sources & Data MCT8 Deficiency Incidence Estimates Conservative Estimate • Multiple cohorts of patients with X- linked mental retardation under study Visser et al., Clin

  28. Slide 28: Appendix 2: Emcitate mode of action and clinical experience

    Appendix 2 Emcitate (tiratricol): Mode of action and clinical experience

  29. Slide 29: Emcitate mechanism of action

    Emcitate mechanism of action with clear scientific and mechanistic rationale and established safety profile Difference normal MCT8 and deficiency of MCT8 Emcitate (tiratricol) – Addressing MCT8 deficiency • Thyroid hormone T3 requires transporters such as MCT8 • Tiratricol is a small molecule thyroi

  30. Slide 30: Discovery of Emcitate (Triac, tiratricol)

    Discovery of Emcitate (Triac, tiratricol) T3 Triac (tiratricol) ©2025 Egetis Therapeutics. All rights reserved. 30

  31. Slide 31: Overview of completed Phase IIb – Triac Trial I

    Overview of completed Phase IIb – Triac Trial I • Evaluate the efficacy and safety of oral administration of tiratricol in male patients with MCT8 deficiency of all ages Primary objective and • Highly significant primary outcome - Change in T3 serum concentrations results • Safe and tolerable • Resu

  32. Slide 32: Consistent, clinically relevant and highly significant results

    Consistent, clinically relevant and highly significant results Triac Trial I: Reached target level serum T3 & improvements in clinically relevant outcome measures 10 T0 (Baseline) 8 T12 (12 month) p < 0.0001 Serum T3 (nmol/l) 6 4 2 Normal range 0 Endpoints Baseline mean (± SD) 12 months mean (± SD)

  33. Slide 33: Triac Trial I: Indication of positive effect on neurocognitive development

    Triac Trial I: Indication of positive effect on neurocognitive development Triac Trial II did not meet its primary endpoints 40 T0 (Baseline) T12 (12 months) 30 GMFM score (%)1) 20 10 0 # # # Patients 1.5 to <4 years 4 to <10 years ≥10 years Age at baseline Source: Groeneweg et al; Lancet D&E 2019 3

  34. Slide 34: Real-world evidence: Long-term efficacy and safety of Emcitate

    Real-world evidence: Long-term efficacy and safety of Emcitate® in MCT8 deficiency patients Published in October, 2021 • Investigator-initiated real-world cohort study at 33 sites conducted by the Erasmus Medical Center • Investigated efficacy and safety of Emcitate in 67 patients with MCT8 deficien

  35. Slide 35: New patient cohort of equal size to the Triac Trial I

    New patient cohort of equal size to the Triac Trial I Long term follow up, up to >6 years Triac Trial I N=46 Triac Trial I patients New patients Available for long-term From managed access program monitoring N=40 N=27 EMC cohort Published in JCEM N=67 35 © 2025 Egetis Therapeutics. All rights reserv

  36. Slide 36: New cohort confirms primary endpoint results in Triac Trial I

    New cohort confirms primary endpoint results in Triac Trial I Fast and durable normalization of T3 values in almost all patients p<0.0001 ©2025 Egetis Therapeutics. All rights reserved. 36 © 2024 Egetis Therapeutics. All rights reserved.

  37. Slide 37: Consistent, clinically relevant and highly significant results across endpoints

    Consistent, clinically relevant and highly significant results across endpoints • Data confirm the positive results from previous study, Triac Trial I • Normalization of serum T3 corresponds to improvement in thyroid hormone status in end target tissues • Beneficial effects are maintained or continu

  38. Slide 38: Triac Trial II objective and design

    Triac Trial II objective and design: Triac Trial II was designed to investigate a potential additional benefit on neurocognitive development in 22 patients with MCT8 deficiency below 30 months of age treated with Emcitate® (tiratricol) during 96 weeks • Confirm findings from Triac Trial I in younges

  39. Slide 39: ReTRIACt Trial Designed to Support NDA Submission

    ReTRIACt Trial Designed to Support NDA Submission Aligned with FDA to Include ReTRIACt Data as Complementary and Not Pivotal • A 30-day, randomized placebo-controlled Patients already on therapy withdrawal study in 15 patients tiratricol tiratricol tiratricol • The study allowed inclusion of patient

  40. Slide 40: ReTRIACt study: Results on primary endpoints

    ReTRIACt study: Results on primary endpoints Largest increase R R Patients ordered by change in serum T3 (nmol/L) R during randomized treatment period* R Placebo range [0.49 : 2.08] No change Tiratricol range D [-0.24 : 0.40] Largest decrease * = change from baseline to rescue or end of randomized t

  41. Slide 41: Triac Trial II Summary

    Triac Trial II Summary • Triac Trial II results: • The numerical improvements versus baseline observed on the primary endpoints of neurocognitive development assessed by the GMFM-88 and BSID-III scales did not show a statistically significant improvement versus historical controls. • The trial confi

  42. Slide 42: Overview of changes in clinical variables during Triac Trial I

    Overview of changes in clinical variables during Triac Trial I 42 T3 within normal range T3 outside normal range ©2025 Egetis Therapeutics. All rights reserved.

  43. Slide 43: Real-world evidence: treatment associated with survival benefits

    Real-world evidence: Tiratricol (Emcitate®) treatment in patients with MCT8 deficiency is associated with survival benefits PRESS • Abstract published ahead of the ETA/ITC Annual Meeting report that treatment with tiratricol (Emcitate®) in patients with MCT8 deficiency is associated with a 3x lower

  44. Slide 44: Post-hoc analysis reports effects on patient-centered outcome measures

    Post-hoc analysis reports effects of tiratricol on patient-centered outcome measures in patients with MCT8 deficiency • According to the Abstract, there were PRESS improvements upon tiratricol treatment reported by caregivers related to improved interaction (22/39), greater alertness (19/39), improv

  45. Slide 45: Appendix 3: Regulatory pathways in EU and US

    Appendix 3 Emcitate® - regulatory pathways in EU and US

  46. Slide 46: Regulatory features of Emcitate for MCT8 deficiency

    Regulatory features of Emcitate for MCT8 deficiency Orphan drug designation for MCT8 deficiency ODD Eligibility: Market exclusivity 10y (EU) & 7y (US) BTD Breakthrough Therapy Designation (FDA) Rare pediatric disease designation (FDA) PRV Eligibility: Priority review voucher upon approval* MAA MAA:

  47. Slide 47: EU Commission approves Emcitate as first and only treatment

    EU Commission approves Emcitate® as the first and only treatment for patients with MCT8 deficiency Jul Aug Aug Sep Sep Dec Feb ETA guidelines Emcitate associated with New post-hoc analysis Patent application to the Secured SEK 300m Positive CHMP opinion for Europen Commission full recommend all pati

  48. Slide 48: Emcitate/tiratricol regulatory pathway in EU/US

    Emcitate/tiratricol regulatory pathway in EU/US Robust data set in an ultra rare genetic disease EMC cohort Triac Trial I Natural history Triac Trial II EMC survival study ReTRIACt study N=46 N=67 N=151 N=22 N>600 N=15 • Completed 2018 • Completed 2021 • Retrospective data, • Open-label, • Basis for

  49. Slide 49: Value enhancing key milestones 2025-2026

    Value enhancing key milestones 2025-2026 Emcitate® 2025-2026 ✓ EU launch, in the first country, Germany, ✓ Completion of US NDA submission MCT8 May 1, 2025 ✓ Japan – Development plan agreed with PMDA deficiency ✓ Türkiye partnership signed with Er-Kim • US Patent granted - Processes and compounds ✓

  50. Slide 50: Appendix 4: Commercial opportunity

    Appendix 4 Emcitate® - Commercial opportunity

  51. Slide 51: Emcitate – alleviating patient and societal burden

    Emcitate®– alleviating patient and societal burden Aiming to provide value for both patients and society MCT8 deficiency is a detrimental condition with significant unmet medical need and no approved therapy • Median life-expectancy of MCT8 patients is 35 years1 Patients • Patients underweight for a

  52. Slide 52: Tiratricol supplied globally in managed access programs

    Tiratricol supplied globally in managed access programs Managed access programs confirm the significant unmet medical need in MCT8 deficiency • Managed access programs MEDICINES AGENCY ‒ mechanisms to allow early access to a medicine prior to regulatory marketing approval ‒ granted to pharmaceutical

  53. Slide 53: Commercialization possible with lean & agile team

    Commercialization possible with lean & agile team Unique setting for Emcitate in MCT8 deficiency Seizing opportunity for cost-effective value creation Addressing unmet medical need • Targeted stakeholder interactions • Efficiency gains through global-country team coordination No competition External

  54. Slide 54: Emcitate launch by Egetis and partners

    Emcitate® (tiratricol) launch by Egetis and partners Executing the US & European market preparations and launches through the Egetis team To optimize the launch, we will focus our own resources on US and Europe Optimizing additional Japan license deal with countries through partners Fujimoto Türkiye

  55. Slide 55: Step-wise building team to execute on key activities for launch

    Step-wise building team to execute on key activities at the right time for launch success Key projects driven by recognized industry talents recruited to the Egetis Commercial & Medical Affairs Team – Core team brings launch skills and best practices from in total 150+ years at international compani

  56. Slide 56: Focusing on Critical Areas for Launch Success

    Focusing on Critical Areas for Launch Success Aiming to Improve the Lives of MCT8 Deficiency Patients and their Caregivers IDENTIFY PATIENTS ENSURE ACCESS Boost disease awareness, educate on Preparing for broad access to Emcitate as disease*, diagnosis and newborn soon as possible after marketing sc

  57. Slide 57: Expanding disease awareness momentum

    Expanding disease awareness momentum Amplified by External Efforts Constructive dialogues at Scientific community Great work ongoing by several scientific congresses generating more data patient advocacy groups Example from Annual Meeting of the European Thyroid Association Van der Most, F. et al. T

  58. Slide 58: Deliver solid clinical and economic value proposition

    Deliver solid Emcitate clinical and economic value proposition to enable reimbursement & broad access Key for payer assessments to describe burden of disease, unmet need & benefit of treatment High burden of MCT8 Significant unmet medical Emcitate benefit validated by deficiency need physicians and

  59. Slide 59: ETA recommends tiratricol as long-term therapy

    European Thyroid Association (ETA) recommends tiratricol as long-term therapy for all patients with MCT8 deficiency • ETA recommends the use of tiratricol as long-term therapy for all patients with MCT8 deficiency, and for certain patients with RTH-beta. • Inaugural 2024 Guidelines were commissioned

  60. Slide 60: A phased EU launch starting in Germany

    A phased EU launch through in-house commercial organization starting in Germany May 1 Pricing & Reimbursement (P&R) strategy execution in 2 waves, starting with EU4 Deliver the Emcitate clinical and economic value proposition in P&R processes, outlining: Wave 1 • MCT8 deficiency and its rarity Franc

  61. Slide 61: Germany: Benefit assessment and price negotiations

    Germany: Benefit assessment and price negotiations for new drugs follow a strict and transparent process AMNOG Process is well-defined and led by G-BA for benefit assessment and by GKV for price negotiations 4 parties involved in AMNOG process: For orphan drugs: population size and annual therapy co

  62. Slide 62: Germany Launch Strategy

    Germany Launch Strategy Building strong Expert base to advance management of MCT8 deficiency MCT8 deficiency Experts • Engage experts in increasing disease awareness in Germany • Advance collaborative efforts on monitoring and treatment guidance of MCT8 deficiency • Advocate for importance of local

  63. Slide 63: United States: Egetis Priority Market

    United States: Egetis Priority Market From Regulatory Milestone to Commercial Momentum Driving Patient Identification Growth • Deep engagement in key referral centers • Strong KOL and advocacy alignment • Growing identified patient pool (>140) Expanded Access Strengthening Launch Readiness • 17 acti

  64. Slide 64: US: Annual Treatment Costs and Strength of Evidence

    US: Annual Treatment Costs and Strength of Evidence Representative analogues Product Disease Estimated avg. annual treatment cost (WAC) Impact of strength of evidence on price Oxlumo® Primary ~$623K Biologic hyperoxaluria type 1 • Morbidity-driven disease burden, supported by Hypophosphatasia surviv

  65. Slide 65: Appendix 5: Emcitate partnerships

    Appendix 5 Emcitate partnerships

  66. Slide 66: License agreement with Fujimoto for Emcitate in Japan

    Advancing rest of world with license agreement with Fujimoto for Emcitate in Japan • Highly suitable partner in Fujimoto PRESS ‒ Private company in Osaka, Japan, founded in 1933 ‒ Significant experience from successfully registering and launching medicines for Blood, Neurological and Orphan diseases

  67. Slide 67: Emcitate launch by Egetis and partners

    Emcitate® (tiratricol) launch by Egetis and partners Executing the US & European market preparations and launches through the Egetis team To optimize the launch, we will focus our own resources on US and Europe Optimizing additional Japan license deal with countries through partners Fujimoto Türkiye

  68. Slide 68: Appendix 6: Potential for indication expansion into RTH-beta

    Appendix 6 Potential for indication expansion into RTH-beta

  69. Slide 69: Resistance to Thyroid Hormone type Beta (RTH-β)

    Resistance to Thyroid Hormone type Beta (RTH-β) Potential indication expansion for Emcitate into non-overlapping patient population Characteristics of RTH-β Emcitate as potential treatment for RTH-β • Caused by mutations in thyroid hormone receptor • Emcitate efficacious in restoring signaling in ma

  70. Slide 70: The Feedback Loop in RTH

    “The Feedback Loop” in RTH Thyroid Stimulating Hormone (TSH) - + Thyroid Hormones T4 and T3 Example levels Normal Levels TSH NORMAL RANGE 4.0 0.27-4.2 T4 HIGH 45 12-22 T3 HIGH 22 3.1-6.8

  71. Slide 71: Increased Mortality RTHβ

    Increased Mortality RTH𝛽 2.84 3.49 6.35 Welsh cohort 55 patients RTH Beta 2750 Age and sex matched controls Median age 1st event 56 vs 67 ©2025 Egetis Therapeutics. All rights reserved. 71 Okosieme, Lancet Diabetes Endocrinology 2023. PMID 37475119

  72. Slide 72: Thyroid Hormone Concentration on Triac Treatment

    Thyroid Hormone Concentration on Triac Treatment fT4T4 Baseline to Nadir TT3 Baseline to Nadir fT4 Free Concentration Total T3 Concentration 60 (LCMS) A1 A1 A2 A2 3 50 A3 A3 A4 A4 A5 A5 40 A6 A6 TT3 (nmol/L) fT4 (pmol/L) A7 2 A7 30 A8 A8 20 1 10 0 0 Baseline 1 Nadir 2 Baseline 1 Nadir2 ©2025 Egetis

  73. Slide 73: Appendix 7: Financials

    Appendix 7 Financials

  74. Slide 74: Strong financial foundation for strategic execution

    Strong financial foundation for strategic execution Solid cash position Directed share issue Oct. 2025 of SEK 183m (USD 19m) • Cash position December 31, 2025: SEK 216 million • Oversubscribed with participation from new & existing investors • Number of outstanding shares: 395,161,938 • Market Cap:

  75. Slide 75: Financial Overview – Fourth Quarter and 12-months

    Financial Overview – Fourth Quarter and 12-months • Total revenue ‒ FY-2025 of 62.4 MSEK vs. 46.1 MSEK for 2024, +40% YoY CER ‒ Q4-2025 of 17.9 MSEK vs. 10.8 MSEK for Q4-2024, +74% YoY CER • Cost of goods sold impacted by non-recurring milestone and the initiation of MSEK 2025 2024 2025 2024 intangi

  76. Slide 76: FDA granted Rare Pediatric Disease designation to tiratricol

    FDA granted Rare Pediatric Disease designation to tiratricol US Rare Pediatric Disease Priority Review Voucher (PRV) provides a ~$200m opportunity Overview of PRV Examples of PRVs sold • The FDA grants Rare Pediatric Disease designation (RPD) Seller Buyer Value Year to therapies for serious or life-

  77. Slide 77: Egetis submits patent application to the USPTO

    Egetis submits patent application to the USPTO • Patent application for “Processes of Preparation” of tiratricol PRESS • Processes and compounds described in the patent application • If granted, this would be a significant patent for Egetis • Generally, the exclusivity term of a new patent is 20 yea

  78. Slide 78: Appendix 8: The attractiveness of the orphan drug segment

    Appendix 8 The attractiveness of the orphan drug segment

  79. Slide 79: Orphan drug segment – a highly attractive opportunity

    Orphan drug segment – a highly attractive opportunity Shorter clinical development time1 Higher attainable prices2 Orphan drugs attractive returns5 Phase II to launch Average # of years Mean cost per patient and year (USDk) 143,4 152,2 150,9 128,1 134,5 ORPHAN 3.8 years 1.7x 10,3% 31,2 32,4 33,7 NON

  80. Slide 80: Orphan drug segment – a highly attractive opportunity

    Orphan drug segment – a highly attractive opportunity Orphan drug designation is awarded to • Less extensive clinical trials 1 products targeting limited disease populations1 Development • Agile and faster development process • Lower costs • Lower development risk 2 More than 7,000 known rare diseas

  81. Slide 81: CAGR estimates of total pharmaceutical market vs orphan

    CAGR estimates of total pharmaceutical market vs orphan The global orphan or rare disease market size was valued at an estimated USD 140 – 150 bn and is expected to grow at 10-14% CAGR over the coming five years. Source: EvaluatePharma, Pareto. 81 ©2025 Egetis Therapeutics. All rights reserved.

  82. Slide 82: Appendix 10: Leadership Team and Board of Directors

    Appendix 10 Leadership Team and Board of Directors

  83. Slide 83: Leadership team with global experience & proven track record

    Leadership team with global experience & proven track record Nicklas Westerholm Kristina Sjöblom Nygren, MD Katayoun Welin-Berger, PhD CEO CMO VP Technical Operations • Joined 2017 • Joined 2020 • Joined 2023 • AstraZeneca 1995-2017 • CMO, Head of Development at Santhera • VP Operations at Callidita

  84. Slide 84: Board of directors

    Board of directors Mats Blom Margarida Duarte Chair of the board since 2024 Board member since 2025 • Shares in Egetis: 3,499,762 • Shares in Egetis: 0 • BA, Business Administration & Economics, Lund University; • BS in Pharmaceutical Sciences & Executive Master’s degree MBA, IESE University of Nava

  85. Slide 85: Termination of discussions regarding a potential acquisition of the Company

    Termination of discussions regarding a potential acquisition of the Company Announcement published on May 23, 2023 • Discussions, triggered by an unsolicited approach by an external party, have taken place between certain external parties and Egetis regarding a potential acquisition of the Company •

  86. Slide 86: Appendix 11: Paracetamol overdose and clinical experience with Aladote

    Appendix 11 Paracetamol/Acetaminophen overdose and clinical experience with Aladote * In-house development of Aladote has been parked until Emcitate MCT8 deficiency submissions have been completed

  87. Slide 87: Aladote – to prevent acute liver injury caused by paracetamol poisoning

    Aladote® – To prevent acute liver injury caused by paracetamol poisoning* • Paracetamol poisoning is one of the most common overdoses with >175,000 hospital admissions globally per annum • No adequate treatment exists for increased risk patients • Orphan drug designation (ODD) granted in the US & EU

  88. Slide 88: Paracetamol/acetaminophen poisoning – no adequate treatment

    Paracetamol/acetaminophen poisoning – no adequate treatment for increased-risk patients What is • Minimum toxic dose of paracetamol/acetaminophen in adults is only 7.5g paracetamol/ acetaminophen • Risk factors include malnutrition, alcoholism and consumption of other medications poisoning? • Parace

  89. Slide 89: Orphan drug candidate

    Orphan drug candidate with clear scientific and mechanistic rationale Early presenters (<8h) Late presenters (>8h) are at increased-risk for liver injury NAC treatment effective against liver injury NAC treatment + Aladote® to prevent liver injury • Liver glutathione (GSH) replenished by NAC, toxic

  90. Slide 90: Overview of completed Phase Ib/IIa

    Overview of completed Phase Ib/IIa • Met primary endpoint of safety tolerability in the combination of Aladote® and NAC Primary • Results presented at the 58th Annual Meeting of the Society of Toxicology, EASL objective and ILC in April, Vienna and published in Lancet’s journal EBioMedicine in 2019

  91. Slide 91: Positive proof-of-principle Phase Ib/IIa results

    Positive proof-of-principle Phase Ib/IIa results Indicates that Aladote may reduce liver injury Safety & tolerability Liver injury – ALT1 pre-defined secondary outcome NAC + 2 NAC + 5 NAC + 10 NAC + 2 NAC + 5 NAC + 10 % of patients needing mol/kg mol/kg mol/kg mol/kg mol/kg mol/kg additional N

  92. Slide 92: Aladote demonstrates reduced liver injury on exploratory biomarkers

    Aladote® demonstrates consistent results of reduced liver injury as measured by exploratory biomarkers K18K18 ccK18 ccK18 miR-122 miR-122 10 10 10 Relative change from baseline Relative change from baseline Relative change from baseline NAC alone NAC alone NAC alone NAC and 2umol/kg NAC and 2umol/kg

  93. Slide 93: Aladote – Regulatory pathway to submissions in EU and US

    3. Aladote® - Regulatory pathway to submissions in EU and US* * In-house development of Aladote has been parked until Emcitate MCT8 deficiency submissions have been completed

  94. Slide 94: ALBATROSS: Phase IIb/III study for US/EU regulatory submission

    ALBATROSS: Phase IIb/III study for US/EU regulatory submission* • Patients who have overdosed on paracetamol with increased Patient risk of liver damage due to late arrival at hospital (> 8h) who population need treatment with NAC NAC regimen • Approved 21 hours NAC regimen Treatment • 4 groups in c

  95. Slide 95: ALBATROSS: Aladote Phase IIb/III study design

    ALBATROSS: Aladote Phase IIb/III study design Seamless Phase IIb/III design Based on the acetaminophen/paracetamol levels eligible patients will be randomised in a 1:1:1:1 ratio to one of the 4 treatment arms in combination with NAC: 35 35 55 140 pts interim 250 pts 35 analysis 55 35 • Stop the stud

  96. Slide 96: Aladote clinical development timelines

    Aladote clinical development timelines Orphan Drug Designation EU • Interim analysis CTA pivotal • Recruitment completed Phase IIb/III study and topline results 2022 tbc tbc tbc • Start pivotal Phase • Regulatory submissions IIb/III study (after Europe/US Emcitate submissions have been completed) •

  97. Slide 97: Aladote – Commercial opportunity

    3. Aladote® - Commercial opportunity

  98. Slide 98: Aladote – alleviating patient and societal burden

    Aladote– alleviating patient and societal burden Aiming to provide value for both patients and society POD is a life threatening condition with remaining medical needs • POD (paracetamol/acetaminophen overdose) can lead to acute liver failure, liver transplant or death Patients • In US and UK togeth

  99. Slide 99: Commercialisation of Aladote for high-risk POD patients

    Commercialisation of Aladote for high-risk POD patients Very cost-effective since possible to launch through members of Emcitate team Favorable conditions for launch success Addressing life-threatening condition • Anologue antidotes priced at $3.5k – 50k Addressing unmet medical need • National emer

  100. Slide 100: Analogue antidotes priced at $3.5k – 50k

    Analogue antidotes priced at $ 3.5k – 50k National emergency hospital stocking guidelines - opportunity for rapid market penetration • Various antidotes, e.g. vs. drug overdosing, metal poisoning, snake bites and reversal of anticoagulant treatment effects • Limit morbidity/mortality when used withi

  101. Slide 101: Thank you!

    Thank you! Egetis Therapeutics egetis.com karl.hard@egetis.com ©2025 Egetis Therapeutics. All rights reserved. 101

Egetis Therapeutics — Investor Presentation (March 2026) on 6ix